Glaukos Corp (GKOS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Glaukos Corp (GKOS) has a cash flow conversion efficiency ratio of -0.019x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-12.53 Million) by net assets ($670.93 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Glaukos Corp market cap and net worth for the company's overall valuation and market capitalisation.
Glaukos Corp - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Glaukos Corp's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Glaukos Corp Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Glaukos Corp ranked by their cash flow conversion efficiency. Explore Glaukos Corp (GKOS) cash flow quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SalMar ASA
OL:SALM
|
0.108x |
|
Anji Microelectronics Tech Co Ltd
SHG:688019
|
0.004x |
|
JSW Infrastructure Limited
NSE:JSWINFRA
|
0.112x |
|
Adani Total Gas Limited
NSE:ATGL
|
0.017x |
|
Ternium SA ADR
NYSE:TX
|
0.013x |
|
Sartorius Aktiengesellschaft
F:SRT
|
0.049x |
|
Spyre Therapeutics Inc.
NASDAQ:SYRE
|
-0.063x |
|
Shandong Hualu Hengsheng Chemical Co Ltd
SHG:600426
|
0.026x |
Annual Cash Flow Conversion Efficiency for Glaukos Corp (2012–2025)
The table below shows the annual cash flow conversion efficiency of Glaukos Corp from 2012 to 2025. View Glaukos Corp (GKOS) stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $656.15 Million | $-46.34 Million | -0.071x | +11.67% |
| 2024-12-31 | $766.93 Million | $-61.32 Million | -0.080x | +36.08% |
| 2023-12-31 | $461.77 Million | $-57.76 Million | -0.125x | -100.39% |
| 2022-12-31 | $530.00 Million | $-33.08 Million | -0.062x | -248.33% |
| 2021-12-31 | $587.15 Million | $24.71 Million | 0.042x | +222.18% |
| 2020-12-31 | $667.45 Million | $-22.99 Million | -0.034x | -6184.16% |
| 2019-12-31 | $673.27 Million | $-369.00K | -0.001x | -100.51% |
| 2018-12-31 | $173.86 Million | $18.86 Million | 0.109x | -41.21% |
| 2017-12-31 | $138.20 Million | $25.51 Million | 0.185x | +75.85% |
| 2016-12-31 | $117.27 Million | $12.31 Million | 0.105x | +556.64% |
| 2015-12-31 | $95.19 Million | $-2.19 Million | -0.023x | -152.04% |
| 2014-12-31 | $-160.90 Million | $-7.11 Million | 0.044x | -50.52% |
| 2013-12-31 | $-149.04 Million | $-13.30 Million | 0.089x | -96.09% |
| 2012-12-31 | $-8.95 Million | $-20.45 Million | 2.285x | -- |
About Glaukos Corp
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more